Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Harvard Business School
McKesson
Dow
Boehringer Ingelheim

Last Updated: December 16, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206691

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 206691 describes PERPHENAZINE, which is a drug marketed by Pharm Assoc, Anda Repository, Ani Pharms Inc, Mylan, Sandoz, Vintage Pharms, Watson Labs Inc, Wilshire Pharms Inc, Fosun Pharma, Heritage Pharma, Ivax Sub Teva Pharms, Par Pharm, Sun Pharm Industries, and Watson Labs, and is included in forty-six NDAs. It is available from twelve suppliers. Additional details are available on the PERPHENAZINE profile page.

The generic ingredient in PERPHENAZINE is amitriptyline hydrochloride; perphenazine. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amitriptyline hydrochloride; perphenazine profile page.
Summary for 206691
Tradename:PERPHENAZINE
Applicant:Mylan
Ingredient:perphenazine
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 206691
Medical Subject Heading (MeSH) Categories for 206691
Suppliers and Packaging for NDA: 206691
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PERPHENAZINE perphenazine TABLET;ORAL 206691 ANDA Mylan Pharmaceuticals Inc. 0378-5350 0378-5350-01 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-5350-01)
PERPHENAZINE perphenazine TABLET;ORAL 206691 ANDA Mylan Pharmaceuticals Inc. 0378-5351 0378-5351-01 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-5351-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2MG
Approval Date:Apr 14, 2017TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength4MG
Approval Date:Apr 14, 2017TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength8MG
Approval Date:Apr 14, 2017TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
McKinsey
Mallinckrodt
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.